Nitromin

Quick links to important sections

Nitromin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitromin

What is Nitromin? Defining the Active Ingredient and Drug Type

Property Description
Active ingredient Glyceryl Trinitrate (GTN), Nitroglycerin
Primary Forms Sublingual tablet, translingual spray, transdermal patch
Pharmacological Class Organic Nitrate Vasodilator, Antianginal Agent
General Purpose Reduces heart workload and improves oxygen balance
Origin Synthetic Small Molecule

Nitromin is a medication whose active ingredient is Glyceryl Trinitrate (GTN), which is chemically identical to Nitroglycerin. This drug is classified as an essential medicine and belongs to the Organic Nitrate Vasodilator pharmacological class. It is a single-active-ingredient product, comprising a synthetic small molecule compound. The classification of Glyceryl Trinitrate as an antianginal agent is clinically recognized for its established role in managing vascular conditions where rapid vasodilation is required.


Pharmaceutical Forms and General Therapeutic Purpose

Glyceryl Trinitrate is produced in several distinct dosage forms, including the rapid-acting sublingual tablet and the translingual spray, intended for immediate absorption. Other preparations include the transdermal patch and topical ointment for sustained, prolonged effects. This multi-form availability is a key differentiating feature, allowing for the appropriate route of administration to be selected based on the need for either acute relief or preventative maintenance.

This medication's general purpose is to address temporary heart discomfort by reducing the heart's overall workload. It achieves this by promoting widespread venodilation which decreases the volume of blood the heart has to pump, helping to restore the necessary equilibrium between the heart's need for oxygen and the available blood supply.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Nitromin?

Possible side effects and safety information

Official regulatory documentation defines the safety profile of Nitromin (Glyceryl Trinitrate) by classifying adverse reactions based on their frequency and grouping them into System-Organ Classes (SOCs).

Frequency-Classified Adverse Reactions

The most frequent effects are a direct consequence of the medicine's vasodilatory action.

Classification Examples of Documented Effects
Very Common (≥1/10) Headache
Common (≥1/100 to <1/10) Dizziness, Somnolence, Hypotension, Tachycardia, Orthostatic hypotension, Asthenia
Uncommon (≥1/1,000 to <1/100) Nausea, Vomiting, Circulatory collapse, Enhanced angina pectoris symptoms, Allergic skin reactions

These effects primarily map to Nervous System Disorders (headache, dizziness), Vascular Disorders (hypotension, circulatory collapse), and Cardiac Disorders (tachycardia).

Serious Safety Considerations

Serious adverse reactions documented in regulatory sources include Syncope (fainting), Circulatory collapse, and the rare potential for Methemoglobinemia.

Time-Related Patterns and Restrictions

Headaches, although Very Common and dose-related, are often most prominent at the start of therapy and generally subside with continued use. Regulatory labeling notes that drug tolerance (a diminished effect) may develop with prolonged high-level exposure.

Safety is strictly constrained by a number of contraindications. The medicine must not be used in individuals with conditions such as Severe Anemia, Increased Intracranial Pressure, Acute Circulatory Failure or Shock, or Hypertrophic Obstructive Cardiomyopathy. Use is absolutely contraindicated alongside Phosphodiesterase-5 (PDE-5) inhibitors due to the risk of severe, life-threatening hypotension.

Population-specific safety statements note that efficacy and safety are not established for pediatric use, and older adults may be at an increased risk for certain adverse effects like postural hypotension.

Overdose and Emergency Response

Overdose of Nitromin (Glyceryl Trinitrate) primarily causes an exaggerated form of its therapeutic effect, resulting in severe and potentially life-threatening symptoms. Officially documented overdose manifestations include severe hypotension, a persistent throbbing headache, vertigo, visual disturbance, nausea, and vomiting. Skin changes may include flushing followed by a cold, cyanotic appearance. Tachycardia (rapid heartbeat) or paradoxical bradycardia (slow heartbeat) are also possible clinical signs.

Life-threatening outcomes include circulatory collapse and shock. High-dose exposure is associated with the risk of methaemoglobinaemia, a serious blood disorder, and massive overdose may lead to central nervous system effects such as convulsions.

Immediate medical attention is required for any suspected overdose. For the rapid-acting forms, regulatory guidance mandates seeking prompt medical help if chest pain persists after a total of three doses administered over a 15-minute period.

There is no specific antagonist for the primary vasodilator effects. Treatment is symptomatic and supportive, focused on countering severe hypotension, typically through fluid volume expansion and elevating the patient's legs. The official label explicitly advises against the use of epinephrine or other arterial vasoconstrictors in managing overdose-induced hypotension. Hospital monitoring is required, and specialized consideration is necessary for infants and patients with pre-existing renal disease or congestive heart failure.

Therapeutic Uses of Nitromin

Quick Facts: Nitromin

  • Relieves: Acute episodes of chest discomfort (angina pectoris).
  • Prevents: Angina that may be brought on by physical activity or stress.
  • Manages: Symptoms associated with unstable angina and acute left-sided heart failure (in appropriate formulations).

Nitromin (which contains the active substance nitroglycerin/glyceryl trinitrate) is a prescription medication utilized in therapeutic contexts to address cardiovascular conditions. The primary approved use of this medicine is for the relief of an acute episode of angina pectoris, often referred to as chest discomfort or tightness caused by reduced blood flow to the heart muscle.

It is also used as a prophylactic measure—meaning it is taken before engaging in activities that are reasonably anticipated to lead to an anginal episode, such as physical exertion or emotional stress. This helps to prevent the onset of symptoms.

In hospital settings, specific formulations are indicated for the control of unstable angina and to support the management of certain forms of congestive heart failure, including acute left-sided heart failure and conditions associated with acute myocardial infarction.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Nitromin (Nitroglycerin)

Official regulatory information strictly defines the populations who must not use Nitromin and those for whom use is conditional. These rules are based on formal contraindications detailed in government-approved labeling.

Absolute Exclusions (Contraindications)

The medicine must not be used by patients who have any of the following conditions or are taking these medications:

  • Concurrent Drug Therapy: Taking any Phosphodiesterase type 5 (PDE5) inhibitor (e.g., sildenafil, tadalafil) or the soluble guanylate cyclase (sGC) stimulator riociguat.
  • Severe Medical Conditions: Diagnosed with severe anemia, significantly increased intracranial pressure (such as from a head injury or cerebral hemorrhage), or experiencing acute circulatory failure or shock.
  • Allergy: Known hypersensitivity to nitroglycerin, other nitrates/nitrites, or any ingredient in the product.

Populations Requiring Conditional Use

Use requires careful medical consideration and is often subject to specific precautions in these groups:

  • Low Blood Pressure: Patients with hypotension or those who are volume-depleted.
  • Pediatric Patients: Use in children is often not established or approved.
  • Pregnancy and Lactation: Use during pregnancy or while breastfeeding should only occur if the potential benefit justifies the potential risk, as human data are limited.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes officially documented interaction patterns for Nitromin (Glyceryl Trinitrate) found in regulatory labeling.


Formal Contraindicated Combinations

Co-administration is Contraindicated with two major drug classes due to the official documentation of a potentiation of hypotensive effects (a severe, dangerous drop in blood pressure):

  • Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., Sildenafil, Tadalafil)
  • Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat)

Documented Pharmacodynamic and Exposure Interactions

Co-administration with other hypotensive agents (including Beta-Blockers, Diuretics, and Tricyclic Anti-depressants) results in an additive hypotensive effect, as noted in official documents. This additive effect is also documented for the concurrent use of Alcohol (Ethanol).

Interaction effects that alter plasma levels are also documented:

  • Aspirin may decrease the clearance of sublingual Glyceryl Trinitrate, potentially enhancing its effects.
  • Intravenous Nitromin reduces the anticoagulant effect of Heparin and decreases the thrombolytic effect of Alteplase, representing an interaction with therapeutic effect.
  • Anticholinergic drugs may reduce the effectiveness of sublingual forms due to diminished salivary secretions, affecting the physical dissolution of the tablet.

Population-Specific Note: Official labeling notes that the time frame for avoiding nitrates after PDE-5 Inhibitor use may be prolonged in patients with hepatic impairment or severe renal impairment due to altered drug clearance.

Mechanism of Action

Bioactivation and the cGMP Signaling Cascade

Nitromin (Glyceryl Trinitrate, GTN) functions as an inactive prodrug that requires bioactivation by the enzyme Mitochondrial Aldehyde Dehydrogenase 2 ( ALDH2) to release the signaling molecule Nitric Oxide ( NO). This NO acts as an activator of Soluble Guanylate Cyclase ( sGC). This action triggers the cGMP pathway cascade, leading to a reduction in calcium within smooth muscle cells and causing vessel walls to relax.


Vasodilation and Workload Modulation

The cGMP-mediated muscle relaxation results in widespread vasodilation, which affects the peripheral veins preferentially (venodilation). This widening causes blood to pool away from the heart, leading to a significant decrease in the volume of blood returning to the heart (downarrow preload). By lowering the heart's filling pressure and the subsequent wall tension, this mechanism decreases the tension on the heart muscle walls, which consequently modulates the heart's oxygen requirement.


⏳ Mechanism Constraint: Nitrate Tolerance

The drug's mechanism is subject to a limitation known as tachyphylaxis (nitrate tolerance) upon continuous exposure. This is primarily a biochemical constraint rooted in the consumption and functional depletion of the essential sulfhydryl ( -SH) groups required as cofactors for the ALDH2 enzyme to continue generating NO. This loss of NO generating capacity affects the cGMP pathway, resulting in a reduction of the vasodilatory response.

Dosage and Administration Information

How to Use Nitromin: Administration Guidelines

Nitromin, which contains Glyceryl Trinitrate (Nitroglycerin), is utilized through several distinct administration routes depending on the therapeutic need. The primary approved routes include sublingual (SL), translingual, transdermal, and intravenous (IV) delivery.

Administration Scope

Instruction Entity Description
Dosing for Acute Relief (SL/Translingual) A single dose typically ranges from 0.3 mg to 0.6 mg or 400 mcg per metered spray.
Frequency for Acute Relief Dosing may be repeated every 5 minutes as needed, not to exceed a maximum of 3 doses within a 15-minute period.
IV Infusion Regimen Dosing is initiated at 5 mcg/minute and is adjusted in increments based on clinical response, typically maintaining a dose range of 5 to 100 mcg/minute.
Administration Context For sublingual use, the patient should ideally rest in a sitting position. The dose must not be chewed or swallowed.

Use Patterns for Continuous Therapy

For continuous, maintenance therapy, such as with a transdermal patch, the medicine is applied once daily. To prevent the body from developing pharmacological tolerance, the regimen requires a necessary, uninterrupted nitrate-free interval of 10 to 12 hours each day.

Special Procedural Requirements

The IV solution requires dilution prior to administration and must be delivered using non-PVC tubing to prevent the drug from being absorbed into the plastic, ensuring the correct dose is delivered. Pediatric patients receiving IV treatment follow a specific dosing regimen typically starting at 0.25 to 0.5 mcg/kg/minute.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nitromin

This overview summarizes the research that was conducted on Glyceryl Trinitrate (the active ingredient in Nitromin), focusing on the types of studies available and what they have explored, without offering clinical advice or guidance.


Evidence for Acute Relief of Chest Discomfort (Angina Pectoris)

The primary evidence for addressing temporary chest discomfort was evaluated in short-term randomized controlled trials (RCTs). These research efforts were primarily used in research exploring how quickly symptom changes occur following application in studies. Studies focused on precise metrics, such as the time elapsed until a patient reported complete resolution of discomfort, and changes in vascular function. Findings describe patterns observed in the studies where rapid measurements of symptom resolution were reported. The structure of this evidence is consistently rated as High.


Evidence for Preventing Effort-Induced Angina (Prophylaxis)

Research exploring the preventative uses was evaluated in controlled trials that focused on outcomes reflecting daily functioning or activity level. Specifically, research measured patients’ functional ability by assessing the total time they could exercise without symptoms and tracked objective ischemic markers. The evidence structure for research addressing these functional metrics is also assigned a High level by regulatory bodies.


Long-Term Follow-up and Durability of Effect

Studies on Nitromin are largely focused on short-term or episodic symptom patterns. Consequently, long-term effects are not fully established or well-characterized in regulatory documents. The primary research concerning durability relates to the phenomenon of tolerance, where the body's responsiveness may lessen with continuous exposure. Research designs included observation periods without the medicine to document the return of responsiveness, confirming that follow-up durations were limited in exploring continuous, long-term patterns.


Remaining Evidence Gaps and Areas of Uncertainty

The research landscape is not fully complete, particularly regarding certain chronic uses and patient groups. Key gaps include optimal dosing protocols for different presentations of acute heart failure, where comparative evidence is lacking. Additionally, certainty remains low for the long-term impact on hard outcomes, as this information is often based on older or observational evidence. Subgroup findings are uncertain in specific populations, such as the elderly, where some retrospective data was associated with different outcome patterns.

Key Studies & References

  1. Low-dose versus high-dose intravenous nitroglycerin in the treatment of sympathetic crashing acute pulmonary oedema: a systematic review and meta-analysis...
  2. MedlinePlus: Nitroglycerin Sublingual (Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Nitromin (FAQ)

Q: Can I take simple pain relievers (like Tylenol or Advil) while on Nitromin?

A: Official information does not formally list an interaction between nitroglycerin and common pain relievers such as acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs). However, official product information does note known additive hypotensive effects when combined with various blood pressure lowering agents.

Q: What kind of monitoring (like blood tests) is typically done while taking Nitromin?

A: The regulatory labeling identifies methemoglobinemia as a rare but serious adverse reaction. Monitoring may be necessary under certain clinical conditions, such as during high-dose therapy or if a serious reaction is suspected. The treating healthcare professional determines the need for specific tests.

Q: Are there any known issues with stopping Nitromin suddenly?

A: Regulatory documents describe a phenomenon where true physical dependence has been demonstrated in cases of high, continuous exposure to nitrates. This concern is distinct from the development of drug tolerance. Temporary withdrawal in some studies has been associated with decreased exercise tolerance, and enhanced angina symptoms are listed as an uncommon adverse effect.

Q: Does Nitromin affect blood pressure in people without a known heart condition?

A: Nitromin is classified as a powerful vasodilator, meaning it works by relaxing and widening blood vessels throughout the body. This action is its fundamental mechanism and can lead to a drop in systemic blood pressure (hypotension). This effect may occur even in individuals without a pre-existing heart condition, particularly when standing upright.

Q: Do you feel dizzy when you first start taking Nitromin?

A: Dizziness and lightheadedness are listed as common side effects in the official product information. Official regulatory advice notes that administration should occur while the patient is at rest, typically sitting down, as people may experience these symptoms soon after applying the tablet or spray.

Q: How long does it typically take for Nitromin to start working?

A: Official administration guidelines describe a rapid onset of action, often measured in minutes, for acute relief forms. Studies focused on precise metrics, such as the time elapsed until a patient reported symptom change.

Q: Can Nitromin be taken by people who are sensitive to certain dyes or fillers?

A: Official regulatory documents strictly contraindicate use if a person has a known hypersensitivity or allergy to the active ingredient (nitroglycerin), other nitrates, or any other ingredient in the product. Patients should review all components to ensure they can safely rule out an allergic reaction to any non-active ingredients, such as dyes or fillers (excipients).

Q: Is Nitromin known to cause any long-term problems or changes?

A: Regulatory summaries indicate that long-term effects of the drug are not fully established or well-characterized in official documents, as research largely focuses on short-term or temporary use patterns. The main long-term pattern discussed is the development of drug tolerance, where the body’s response lessens with continuous exposure.

Q: Can the effectiveness of Nitromin change over time?

A: Yes. The regulatory documentation describes a known limitation called tachyphylaxis, which is often referred to as nitrate tolerance. This is a biochemical constraint where the body's responsiveness may decrease with continuous exposure, reducing the desired vasodilatory effect.

Q: What happens if I miss a dose of Nitromin? (Informational, non-directive)

A: For continuous-use forms like the transdermal patch, official instructions generally advise applying the missed dose as soon as it is remembered. If, however, it is almost time for the next scheduled dose, the regulatory instruction is to skip the missed dose and resume the normal schedule. No extra doses should be taken to make up for a missed one.

Q: Is it common to feel tired while using Nitromin?

A: Asthenia (a feeling of weakness or lack of energy) and somnolence (drowsiness) are listed as common adverse reactions in official regulatory documents. This means these effects have been reported in between 1% and 10% of users in clinical trials.

Q: Are there any common foods or drinks that should be avoided with Nitromin?

A: The official regulatory label documents an additive hypotensive effect, meaning a greater drop in blood pressure, when Nitromin is used concurrently with alcohol (ethanol). There are no general regulatory warnings specifically against common foods or non-alcoholic beverages.

Q: What is the typical age range of people who are prescribed Nitromin?

A: Official documentation notes that safety and efficacy have not been established for pediatric use. Conversely, warnings note that older adults may be at an increased risk for certain side effects, particularly low blood pressure when standing (postural hypotension), and may require careful monitoring.

Q: Is Nitromin safe to use during hot weather or exercise?

A: Official labeling notes that the drug can be used proactively 5 to 10 minutes before engaging in activities that might cause an acute event, such as exercise. However, regulatory warnings note that the drug can cause a drop in blood pressure (hypotension), which may be intensified by conditions that cause volume depletion, such as heavy sweating in hot weather.

Q: Is Nitromin available as a generic version, and is it the same?

A: Yes, Nitromin’s active ingredient, nitroglycerin, is available in generic formulations for several dosage forms. The FDA requires generic versions to meet standards that ensure they deliver the active ingredient in the same way as the original product.

Q: How long does Nitromin stay in the body after the last dose?

A: Official pharmacokinetic information indicates that Nitromin is cleared from the body very rapidly. The resulting serum half-life for most forms is extremely short, typically ranging from about one to four minutes.

Q: Is Nitromin safe for use in older adults (seniors)?

A: Efficacy and safety have been established, but regulatory warnings note that older adults may be at an increased risk for adverse effects like postural hypotension, which is a significant drop in blood pressure upon standing. Due to this potential risk, use in older adults may be subject to careful clinical monitoring.

Q: What are some reasons why a doctor might switch someone from another drug to Nitromin?

A: Nitromin is a highly effective Organic Nitrate Vasodilator that reduces the heart's workload by causing widespread vein relaxation. This mechanism makes it suitable for use when rapid, immediate action is needed for acute relief or when a patient has not responded adequately to or cannot tolerate another class of medication.

Q: Can I still drive or operate machinery while taking Nitromin?

A: Official safety warnings advise that people should be cautious before driving or operating machinery until they know how the medication affects them. This is because Nitromin may cause dizziness or fainting, due to the potential for impaired ability to perform these tasks.

Q: Is the name Nitromin related to any specific ingredient in the medication?

A: The active ingredient in Nitromin is Glyceryl Trinitrate, which is also known as Nitroglycerin. The trade name for the medication is likely derived from the common 'Nitro-' component found in its chemical name.

Q: Is it possible to become dependent on Nitromin?

A: Official regulatory documents describe that true physical dependence has been demonstrated in industrial workers exposed to high levels of nitrates. Sudden cessation of the drug in these scenarios has been associated with severe adverse effects. This is a separate concern from the development of drug tolerance.

Q: Can Nitromin affect mood or cause emotional changes?

A: Adverse reactions are grouped into categories of affected body systems. While mood or emotional changes are not explicitly listed in official documentation, the labels do report effects that map to Nervous System Disorders, including headaches, dizziness, and somnolence (drowsiness).

Q: What do clinical trials say about the effectiveness rate of Nitromin?

A: Regulatory summaries of clinical trials for acute relief focus on objective outcomes, such as the time elapsed until complete symptom resolution. For preventative use, studies measured functional ability, like the total time a patient could exercise without symptoms, rather than calculating a single quantifiable percentage 'effectiveness rate.'

Q: Can Nitromin be taken on an empty stomach?

A: Official administration instructions for the sublingual forms do not provide specific guidance regarding food intake. However, they emphasize that the tablet must not be chewed or swallowed, and the patient should ideally be resting in a sitting position during administration.

Q: Is Nitromin safe for teenagers?

A: Official regulatory documents strictly state that the safety and efficacy for use in pediatric patients, including teenagers, have not been established.

Q: What is the intended duration of treatment with Nitromin?

A: The intended duration of use varies widely based on the form. For acute relief, use is strictly limited to a maximum of three doses within 15 minutes. For preventative patches, official guidelines require daily use but mandate a 10-to-12-hour nitrate-free interval each day to maintain effectiveness.

Q: Are there any warnings about using Nitromin with caffeine?

A: Official drug interaction lists do not single out caffeine alone as a contraindication. However, an interaction is documented for nitroglycerin used in certain combination products that include caffeine, where caution is advised due to the potential for additive effects in lowering blood pressure.

Q: Is Nitromin a commonly used medication, or is it considered specialized?

A: Nitromin (nitroglycerin) is a foundational drug that the World Health Organization (WHO) classifies as an Essential Medicine. This classification indicates its importance and widespread use in addressing public health needs globally.

Q: Is it normal if I feel a tingling sensation after taking Nitromin?

A: A tingling or tingly feeling is listed among the possible side effects in official product information, particularly with the intravenous (IV) formulation. This sensation is often associated with flushing or a sudden feeling of warmth.

Q: Are there different forms of Nitromin (like a pill, liquid, or injection)?

A: Yes, the active ingredient, Glyceryl Trinitrate, is available in several distinct dosage forms as described in regulatory documents. These include the rapid-acting sublingual tablet, translingual spray, a transdermal patch, and an intravenous (IV) injection solution.

Q: If I have allergies, am I more likely to react to Nitromin?

A: Official documents state that use is strictly contraindicated if a patient has a known hypersensitivity or allergy to nitroglycerin, other nitrates, or any non-active ingredients in the product. This means that a history of allergies requires careful review of all ingredients.

Q: Can Nitromin make existing medical conditions worse?

A: Regulatory documents list specific medical conditions for which the use of Nitromin is strictly contraindicated. This is because the drug is prohibited in conditions such as Severe Anemia and Increased Intracranial Pressure.

Q: How is Nitromin different from a supplement for the same condition?

A: Nitromin is a prescription-only drug, classified as a synthetic small molecule and an Organic Nitrate Vasodilator, which has received formal approval from regulatory bodies. Supplements are subject to different regulatory standards and are not classified as prescription medicines.

Q: Are there studies comparing the results of taking Nitromin vs lifestyle changes alone?

A: Studies for preventative use focused on measuring functional ability, such as the total time a patient could exercise without symptoms, which helps evaluate the impact on daily activities. The structure of this evidence is consistently rated as High by regulatory bodies.

How should Nitromin be stored and disposed of?

How to Store and Dispose of Nitromin

To maintain the potency of Nitromin (Nitroglycerin/Glyceryl Trinitrate), the medication must be stored according to official regulatory labeling. Sublingual tablets require storage at a controlled room temperature, typically 20 C to 25 C, and must be protected from moisture. The tablets must be kept in the original glass container, tightly capped after each use, with the cotton filler discarded immediately upon opening.

All forms must be kept out of the reach of children. Transdermal patches and spray should not be frozen, and patches should not be refrigerated. Used transdermal patches must be folded in half (sticky sides together) and disposed of safely, out of children's reach. Users should consult a healthcare professional regarding the proper disposal of any unused or expired product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nitromin found in:

A-Z Index: